Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1840 for Wilson Disease Liver Copper Assessment
NCT04422431Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- May 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of atn-224 in Wilson disease (WD), sponsored by Alexion Pharmaceuticals. Started Dec 2020; status: completed.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on NCT04422431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04422431.